Abstract
The histamine H3 receptor is a pre-synaptic auto- and hetero-receptor that controls the release of histamine and a variety of other neurotransmitters in the brain. As such, modulation of the histamine H3 receptor is expected to affect wake via control of the release of histamine and to affect cognition via regulation of several other neurotransmitters including acetylcholine and norepinephrine. Over the last several years numerous pre-clinical studies have shown that histamine H3 antagonists promote wakefulness, improve cognition, and in some cases affect food intake. Based on the interest level generated from these early pharmacology studies, and following the cloning and expression of the human histamine H3 receptor, many pharmaceutical companies began drug discovery programs aimed at the identification of histamine H3 antagonists suitable for human clinical trials. These efforts have led to many new chemotypes, and several promising compounds have recently entered the clinic for a variety of conditions, including ADHD, Narcolepsy, EDS associated with Narcolepsy, Cognitive disorders and Schizophrenia. Recent efforts towards the identification and pharmacological characterization of novel histamine H3 antagonists will be discussed.
Keywords: Histamine, histamine H3, wake, cognition, histamine h3 antagonists/inverse agonists
Current Topics in Medicinal Chemistry
Title: Histamine H3 Antagonists as Wake-Promoting and Pro-Cognitive Agents
Volume: 8 Issue: 11
Author(s): Emily M. Stocking and Michael A. Letavic
Affiliation:
Keywords: Histamine, histamine H3, wake, cognition, histamine h3 antagonists/inverse agonists
Abstract: The histamine H3 receptor is a pre-synaptic auto- and hetero-receptor that controls the release of histamine and a variety of other neurotransmitters in the brain. As such, modulation of the histamine H3 receptor is expected to affect wake via control of the release of histamine and to affect cognition via regulation of several other neurotransmitters including acetylcholine and norepinephrine. Over the last several years numerous pre-clinical studies have shown that histamine H3 antagonists promote wakefulness, improve cognition, and in some cases affect food intake. Based on the interest level generated from these early pharmacology studies, and following the cloning and expression of the human histamine H3 receptor, many pharmaceutical companies began drug discovery programs aimed at the identification of histamine H3 antagonists suitable for human clinical trials. These efforts have led to many new chemotypes, and several promising compounds have recently entered the clinic for a variety of conditions, including ADHD, Narcolepsy, EDS associated with Narcolepsy, Cognitive disorders and Schizophrenia. Recent efforts towards the identification and pharmacological characterization of novel histamine H3 antagonists will be discussed.
Export Options
About this article
Cite this article as:
Stocking M. Emily and Letavic A. Michael, Histamine H3 Antagonists as Wake-Promoting and Pro-Cognitive Agents, Current Topics in Medicinal Chemistry 2008; 8 (11) . https://dx.doi.org/10.2174/156802608784936728
DOI https://dx.doi.org/10.2174/156802608784936728 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome
Current Pharmaceutical Design The Valsalva Maneuver and Alzheimers Disease: Is there a link?
Current Alzheimer Research Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Insulin Therapy for Improving Cardiac Surgical Outcomes
Current Drug Targets Gender Differences in Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery Bioactive Peptides - Are There More Antihypertensive Mechanisms Beyond ACE Inhibition?
Current Pharmaceutical Design Antioxidant Phytochemicals in Pulses and their Relation to Human Health: A Review
Current Pharmaceutical Design Synthesis of 3-(2, 8, 9-trioxa-5-aza-1-germatricyclo [3.3.3.0] Undecane-1- yl)-3-(4-hydroxyl-3-methoxyphenyl)-propionic Acid and its Inhibitory Effect on the Cervical Tumor U14 in vitro and in vivo
Medicinal Chemistry Home Oxygen Therapy for the 21st Century
Current Respiratory Medicine Reviews Thyroid Hormones and Cardiovascular System: From Bench to Bedside
Current Drug Therapy <i>Uncaria rhynchophylla</i> and its Major Constituents on Central Nervous System: A Review on Their Pharmacological Actions
Current Vascular Pharmacology Progression of Retinopathy in Type 1 Diabetic Women During Pregnancy
Current Diabetes Reviews Optimising the Use of Non-Invasive Ventilation in the Intensive Care Setting
Current Respiratory Medicine Reviews Complex of Nifedipine with Glycyrrhizic Acid as a Novel Water-Soluble Antihypertensive and Antiarrhythmic Agent
Letters in Drug Design & Discovery The Fetal Cardiac Function
Current Cardiology Reviews Biological Mechanisms Linking Alzheimer's Disease and Type-2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Safety and Efficacy of Dexamethasone Intravitreal Implant (Ozurdex) for the Treatment of Persistent Macular Edema Secondary to Retinal Vein Occlusion in Eyes Previously Treated with Anti-Vascular Endothelial Growth Factors
Current Drug Safety QT Interval Monitoring and Drugs Management During COVID-19 Pandemic
Current Reviews in Clinical and Experimental Pharmacology Optic Nerve and Cerebral Edema in the Course of Diabetic Ketoacidosis
Current Neuropharmacology